about we of week's fourth good are Thank Xinvento. good. And acquisition quarter And this call. joining earnings, and for look everyone. the David, you, morning, which Thank going to talk announced earnings you
pathway, of development healthcare the to diseases. ago time, learn we the do system, the testing, on we setmelanotide describing for hyperphagia the [indiscernible], in then, of journey. of so importance rare the complete means about one societal these about associated Complete in expenditure Since receptor At the decade the the of started of almost the confronts of medical It the However, relative in we patients to genetic lack with that, we live the moment and what want all was in much published of part obesity. shortage individual when effect first the before remarkable reports learned have awareness MCX to living a of almost case family a I this deficiencies, the bias, two company's obesity. with experts, energy POMC deficiency. it by genetic and lack which and the with compounded same reflect
how As people. with BBS can one blind asked when people your obesity child be are may response, kind a be bad to losing their and said, when A site. mother hyperphagia child
her further of describe the challenges at behaviors the were Day who the disease X, a Slide family's with in how her in this So the [indiscernible]. as mother Rhythm preoccupation a week mark life abnormal living two BBS associated the living children challenges hyperphagia. and highlighted as severe of incredible been food we seeking starting with This and child speaker, rare with Disease Rare of since and changed has with guest food
rare. some center of at but events them many know of the And one diseases, Rhythm deserves as is new as therapeutic Obesity Day into option and work. right X, obesity is a Disease way a and careful forefront Rare And thinking Care Day Obesity we that treatment. disease and each Week to just that new brings of disease leads World the which on not evaluation awareness obesity the disease, a March requires these
Slide X.
the our pipeline. expanding year our chapter company geographically hear established next further launch, on in we BBS well. of you with commercial So, continues the through extremely embark as XXX now more for end in to patients for Since an The U.S. go prescribing XXXX from approved diversifying as as and reimbursement. approval than have the FDA stage XXX new received was physicians transformative Rhythm prescriptions from a and June will we Jennifer year XXX Yann, more now than
includes Our have. the continues access. IMCIVREE this regions both paid to POMC opportunity in the Internationally, LEPR. now to available France early eight for date and to in ex-U.S. success quality The teams of confidence we grow. on is markets through speaks also BBS
obesity of compounds. that with of to about expanded in a for develop XXXX. already clinic those Dutch and Phase in acquisition our being believe the readouts which study, working and endocrinologists are no heard looking Phase hypothalamic have [indiscernible] development perfectly of the the opportunity focus We're represents acquisition . capitalized have This in the also with initiated them Rhythm DAYBREAK we company announce with congenital with a Phase as being data our from an hyperinsulinism, we of X on X impact preliminary Phase our on and sites and we to excited the With and forward patients. candidates we execute Xinvento, data our begun Stage pediatric pediatrics are of year in we've and Phase formulation evaluating we XXXX in they to were us Xinvento into for continuing how drug overall from our preclinical well label of data trial setmelanotide have This strategy XXXX, trial the and will excited suite X are expand And the as Monday, to targeting we'll forecast. proof X weekly concentration X concept some now And trial fits X setmelanotide. of strong outstanding screening open portion we this trial. switch are look noted, fit
Slide X.
get Sande, and the of Wigerinck, know a is and tolerability their great Piet CEO and I one impressed where incredibly time. to to advisors. Rhythm importantly, story, the terms have CSO CHI mission van fit the The is a in has opportunity suboptimal, are der made treatments need personal by both obvious. and So scientific in thoughtful Piet unmet she disease of of the clear she effectiveness. was way progress Claudine The available safety, had I and short with was as period pursued her Claudine's the the
lowering disease, genetic presenting which levels as in is a glucose levels. hypoglycemic for insulin death. release of [indiscernible] cell, in glucose presence neonatal insults, treatment infusion. of The is during drop in release beta is the life consciousness levels and repetitive front suppressed. increase brain with glucose dextrose In functioning the trigger CHI glucose loss triggers an continues in low of and in emergency patients blood this may threatening Biologically seizures, release the period levels now which resulting further functions front process damage and with CHI, and and glucose episodes,
or hypoglycemic know that levels one despite Japan, We need patient from XX% being of of medical approximately disease standard per an family day treatment. blood and are in on times Patient an and International of times in and occurring in XX% care. additional of these XX,XXX U.S., week Approximately ultra-rare is This X EU low these conducted more to where the individuals one XX% respectively. patients XX% patients in Organization sugar an per surveys by more the or incidence
with chronic plans will well. forward period in a and potentially who as addition on patients transient this year. look population the presentation hyperinsulism more to to We we of our with there's patients target as another in-depth the In hyperinsulinism, development neonatal large science providing potentially twice later
dose trial This controlled a of XXX for additional Slide screening two-to-one BMI. actively double over blind escalated randomized and X trial an randomized will or change weeks The patients. primary is% Phase be X. then is XX for weeks. to eight setmelanotide HO endpoint Patients is patients in followed placebo.
take enroll, closer probably six month XX to months to will XX skewing to it expect the timeframe. We
patients XX, in of to estimated respectively, a different meeting. on is extension tied the as related impairment of the update their injury We and associated pituitary you in ongoing Slide replacement presentation already hypothalamus forward an the and at term to identified long an need history a for the the look EU, an be based will before and with that MCX hormonal XX,XXX on Rhythm pathway abstract a providing X,XXX to anticipate fall the largely the to year for injury. this end U.S. patients their of with to know, opportunity fundamentally
and of independent Slide trials of Multiple XX. year. switch trials, We'll X out of second progressing is [indiscernible] sub-studies. half noted, at well. look weekly the portion in these as top year we open Phase half this second ongoing, M&A and will enrolling read label the of Both each other in programs four are the this initial data its provide patients in DAYBREAK the line
previously. about are we BBS turn we over our I talked which it Jennifer, before prevalence XX, Slide formally numbers, updating to
the program, we identified It's we ahead population in X,XXX anticipated. that in combined gives at of numbers patients Europe BBS confidence biallelic than frequency on As in pathogenic diagnostic with patients the have is U.S. with population, in that target larger the our of similarly increased experience when Europe. identified order U.S. us and extrapolate of U.S. described, for initial and testing this a launch, URO our with the the rate the of all to to look being originally and is variant patient the the X,XXX where
turn And Jennifer. over to it I'll with that,
